Research ArticleArticle
Open Access
Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary
Kim A. Papp, Boulos Haraoui, Deepali Kumar, John K. Marshall, Robert Bissonnette, Alain Bitton, Brian Bressler, Melinda Gooderham, Vincent Ho, Shahin Jamal, Janet E. Pope, A. Hillary Steinhart, Donald C. Vinh and John Wade
The Journal of Rheumatology February 2019, jrheum.180784; DOI: https://doi.org/10.3899/jrheum.180784
Kim A. Papp
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
Boulos Haraoui
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
Deepali Kumar
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
John K. Marshall
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
Robert Bissonnette
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
Alain Bitton
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
Brian Bressler
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
Melinda Gooderham
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
Vincent Ho
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
Shahin Jamal
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
Janet E. Pope
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
A. Hillary Steinhart
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
Donald C. Vinh
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
John Wade
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen’s University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph’s Health Care, London, Ontario; Centre Hospitalier de l’Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute — McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul’s Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l’Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul’s Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen’s University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph’s Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute — McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary
Kim A. Papp, Boulos Haraoui, Deepali Kumar, John K. Marshall, Robert Bissonnette, Alain Bitton, Brian Bressler, Melinda Gooderham, Vincent Ho, Shahin Jamal, Janet E. Pope, A. Hillary Steinhart, Donald C. Vinh, John Wade
The Journal of Rheumatology Feb 2019, jrheum.180784; DOI: 10.3899/jrheum.180784
Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary
Kim A. Papp, Boulos Haraoui, Deepali Kumar, John K. Marshall, Robert Bissonnette, Alain Bitton, Brian Bressler, Melinda Gooderham, Vincent Ho, Shahin Jamal, Janet E. Pope, A. Hillary Steinhart, Donald C. Vinh, John Wade
The Journal of Rheumatology Feb 2019, jrheum.180784; DOI: 10.3899/jrheum.180784